X0508 4 2025-05-16 false 0001459839 SI-BONE, Inc. SIBN 0001218802 FRANCIS LAURA C/O SI-BONE, INC. 471 EL CAMINO REAL, SUITE 101 SANTA CLARA CA 95050 true true false false Chief Executive Officer true Common Stock 2025-05-16 4 S false 250.00 20.008 D 506511.00 D Common Stock 2025-05-16 4 S false 2028.00 19.6877 D 504483.00 D Common Stock 2025-05-16 4 S false 3785.00 19.662 D 500698.00 D Common Stock 2025-05-16 4 S false 3097.00 19.6781 D 497601.00 D Common Stock 2025-05-16 4 S false 100.00 20.01 D 497501.00 D Common Stock 2025-05-16 4 S false 100.00 20.01 D 497401.00 D Common Stock 2025-05-16 4 S false 2231.00 19.6812 D 495170.00 D Common Stock 2025-05-16 4 S false 794.00 19.4801 D 496399.00 D Common Stock 2025-05-19 4 S false 5412.00 19.487 D 490987.00 D Common Stock 302958.00 I by Trust The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Includes 418,615 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Shares held by The David & Laura Joint Rev Tr. This transaction was executed in multiple trades at prices ranging from $20.00 USD to $20.01 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This transaction was executed in multiple trades at prices ranging from $19.01 USD to $20.005 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This transaction was executed in multiple trades at prices ranging from $19.00 USD to $19.96 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This transaction was executed in multiple trades at prices ranging from $19.01 USD to $20.00 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This transaction was executed in multiple trades at prices ranging from $18.98 USD to $19.955 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $19.26 USD to $19.64 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes 2,023 shares acquired under the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 15, 2025. /s/ Michael A. Pisetsky, Attorney-in-Fact for Laura A. Francis 2025-05-20